News Archive

A novel composite risk model showed that 11 percent of sites had worse-than-expected performance, with patients experiencing higher rates of stroke, major bleeding, kidney injury, and paravalvular leak in the 30 days after undergoing a transcatheter aortic valve replacement.

The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.

Recent evidence suggests that a novel oral anticoagulant plus a P2Y12 inhibitor may be the best treatment pathway for patients with atrial fibrillation undergoing percutaneous coronary intervention. DCRI faculty contributed to a meta-analysis recently published in JAMA Cardiology, which drew data from five clinical trials, including DCRI-led AUGUSTUS, to evaluate the safety and efficacy of four different antithrombotic regimens.

DCRI faculty Adrian Hernandez, MD, MHS, and Frank Rockhold, PhD, along with Duke Forge’s Eric Perakslis, PhD, contributed to a recently published paper in Science suggesting next steps that the National Institutes of Health (NIH) could take in order to expand its leadership in data sharing.

The coronavirus outbreak has limited in-person research, highlighting the need for more flexible, participant-friendly research models that can be conducted virtually.

Former FDA Commissioners Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy, and Scott Gottlieb, MD, made recommendations for how the FDA should respond to the novel co

A paper recently published in JAMA Cardiology details the design of ADAPTABLE, a DCRI-led pragmatic clinical trial that uses many novel elements to efficiently answer a question that has substantial impacts on public health. ADAPTABLE seeks to determine the optimal dose of aspirin for patients with heart disease. Although aspirin has been used as a secondary prevention method for nearly three decades, the question of whether low-dose or high-dose aspirin is more beneficial remains unanswered.

The study sought to simultaneously test a method for identifying individuals at high risk for Alzheimer’s disease while testing the efficacy of a potential treatment aimed at targets affecting cell

A report from an NIH Health Care Systems Research Collaboratory roundtable recently published in 

Although initial results from SECURE-PCI suggested that patients treated with periprocedural loading doses of atorvastatin and undergoing percutaneous coronary intervention (PCI) experienced a reduced risk of major adverse cardiovascular events (MACE), extended follow-up showed no significant difference. The 12-month results, which were recently published in JAMA, expand upon the initial study, which followed patients for 30 days.